Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$0.13
+8.9%
$0.09
$0.06
$0.24
$8.65M0.2395,980 shs280,136 shs
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
$0.50
$0.22
$8.67
$450.52M1.25464,030 shs21,870 shs
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
$2.52
+0.8%
$2.53
$0.82
$3.38
$90.94M1.141.76 million shs1.11 million shs
PolarityTE, Inc. stock logo
PTE
PolarityTE
$0.37
$0.20
$1.90
$1.78M1.15249,591 shs8.50 million shs
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
$0.52
+14.8%
$0.78
$0.36
$737.44
$1.65M0.771.33 million shs2.49 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
+8.92%+111.31%+47.67%+15.66%-29.44%
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
+0.80%+6.78%-2.33%+69.13%+147.06%
PolarityTE, Inc. stock logo
PTE
PolarityTE
0.00%0.00%0.00%0.00%0.00%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
+14.82%+29.03%-34.10%-56.99%-99.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.0651 of 5 stars
0.03.00.00.00.00.00.0
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
1.9978 of 5 stars
3.52.00.00.02.60.00.6
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/AN/AN/AN/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
2.3461 of 5 stars
3.02.00.00.04.00.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.00
N/AN/AN/A
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
0.00
N/AN/AN/A
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
3.00
Buy$9.00257.14% Upside
PolarityTE, Inc. stock logo
PTE
PolarityTE
0.00
N/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
2.00
Hold$350.0067,716.31% Upside

Current Analyst Ratings Breakdown

Latest PTE, WINT, ENZN, MBOT, and IDRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2025
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$30K314.16$0.01 per share11.12$0.04 per share3.18
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/AN/AN/A0.29$0.56 per shareN/A
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
N/AN/AN/AN/A$0.17 per shareN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
$810K0.00N/AN/A$2.30 per share0.00
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/A$38.99 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$780K-$0.01N/AN/AN/A-22.19%-1.28%8/6/2025 (Estimated)
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/A
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
-$11.44M-$0.65N/AN/AN/AN/A-110.27%-94.20%8/13/2025 (Estimated)
PolarityTE, Inc. stock logo
PTE
PolarityTE
-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$1.79M-$823.47N/AN/AN/AN/A-227.93%-56.46%8/18/2025 (Estimated)

Latest PTE, WINT, ENZN, MBOT, and IDRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
-$0.15-$0.08+$0.07-$0.08N/AN/A
5/15/2025Q1 2025
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$39.00-$4.63+$34.37-$4.63$2.20 millionN/A
5/9/2025Q1 2025
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A-$0.01N/A-$0.01N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/AN/AN/AN/AN/A
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/AN/AN/AN/AN/A
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
N/AN/AN/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A
82.17
82.17
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/A
1.56
1.56
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
N/A
16.19
16.19
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/A
4.11
4.11
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/A
0.25
0.25

Institutional Ownership

CompanyInstitutional Ownership
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
12.18%
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
16.30%
PolarityTE, Inc. stock logo
PTE
PolarityTE
11.75%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
29.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A74.21 million73.92 millionNot Optionable
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
3262.36 million59.21 millionOptionable
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
2036.38 million34.65 millionOptionable
PolarityTE, Inc. stock logo
PTE
PolarityTE
427.38 million6.98 millionOptionable
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
303.66 million3.65 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Enzon Pharmaceuticals stock logo

Enzon Pharmaceuticals OTCMKTS:ENZN

$0.13 +0.01 (+8.92%)
As of 06/30/2025 03:56 PM Eastern

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Idera Pharmaceuticals stock logo

Idera Pharmaceuticals NASDAQ:IDRA

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Microbot Medical stock logo

Microbot Medical NASDAQ:MBOT

$2.52 +0.02 (+0.80%)
As of 06/30/2025 04:00 PM Eastern

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

PolarityTE stock logo

PolarityTE NASDAQ:PTE

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Windtree Therapeutics stock logo

Windtree Therapeutics NASDAQ:WINT

$0.52 +0.07 (+14.82%)
As of 06/30/2025 04:00 PM Eastern

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.